We are live on ! Find out more

Penumbra

PEN

Market cap $12.5B

318.48 USD

+0.05

0.02%

At close Updated Sep 16, 3:49 PM EDT

1 day

0.02%

5 days

-0.28%

1 month

-2.66%

3 months

0.01%

6 months

-5.27%

Year to date

2.93%

1 year

21.11%

5 years

9.35%

10 years

331.9%

About: Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.

Employees: 4,700

Healthcare Medical Devices

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 63.6%

Neutral 36.4%

Negative 0%

Zacks Investment Research

Reasons to Retain Penumbra Stock in Your Portfolio for Now

PEN's portfolio expansion and international growth support momentum, while rising costs, FX exposure and margin pressure remain key risks.

Reasons to Retain Penumbra Stock in Your Portfolio for Now

Zacks Investment Research

TFX vs. PEN: Which Stock Is the Better Value Option?

Investors interested in Medical - Instruments stocks are likely familiar with Teleflex (TFX) and Penumbra (PEN). But which of these two stocks is more attractive to value investors?

TFX vs. PEN: Which Stock Is the Better Value Option?

Zacks Investment Research

TFX or PEN: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Instruments stocks are likely familiar with Teleflex (TFX) and Penumbra (PEN). But which of these two companies is the best option for those looking for undervalued stocks?

TFX or PEN: Which Is the Better Value Stock Right Now?

Zacks Investment Research

TFX vs. PEN: Which Stock Is the Better Value Option?

Investors interested in Medical - Instruments stocks are likely familiar with Teleflex (TFX) and Penumbra (PEN). But which of these two stocks presents investors with the better value opportunity right now?

TFX vs. PEN: Which Stock Is the Better Value Option?

Penumbra, Inc. Reports Second Quarter 2026 Financial Results

ALAMEDA, Calif., July 30, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2026.

Penumbra, Inc. Reports Second Quarter 2026 Financial Results

THUNDER Study Demonstrates Penumbra's THUNDERBOLT is Safe and Effective for Stroke Care

First and only CAVT device for stroke demonstrated high revascularization rates, short procedure times and low complication rates ALAMEDA, Calif., July 22, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced the results of THUNDER, an Investigational Device Exemption (IDE) study, to evaluate the safety and effectiveness of THUNDERBOLT™, the company's novel computer assisted vacuum thrombectomy (CAVT™) system, in stroke patients with emergent large vessel occlusion (ELVO).

THUNDER Study Demonstrates Penumbra's THUNDERBOLT is Safe and Effective for Stroke Care

3 Medical Device Stocks Giving Investors a Different Healthcare Play

When investors think of the health care sector, most imagine the stability of pharmaceutical giants or the high-risk/high-reward profile of up-and-coming clinical stage drug developers. Medical device companies operate within a unique ecosystem and are often easy to overlook.

3 Medical Device Stocks Giving Investors a Different Healthcare Play

Zacks Investment Research

IQV vs. PEN: Which Stock Is the Better Value Option?

Investors interested in stocks from the Medical - Instruments sector have probably already heard of IQVIA Holdings (IQV) and Penumbra (PEN). But which of these two stocks is more attractive to value investors?

IQV vs. PEN: Which Stock Is the Better Value Option?

First Patient Enrolled in Penumbra's FORWARD Study Evaluating Mechanical Thrombectomy and Computer Assisted Vacuum Thrombectomy for Distal Acute Ischemic Stroke

ALAMEDA, Calif., July 7, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced the initiation of its FORWARD study, an international, real world prospective, multi-center study.

First Patient Enrolled in Penumbra's FORWARD Study Evaluating Mechanical Thrombectomy and Computer Assisted Vacuum Thrombectomy for Distal Acute Ischemic Stroke

Zacks Investment Research

GMED vs. PEN: Which Stock Should Value Investors Buy Now?

Investors looking for stocks in the Medical - Instruments sector might want to consider either Globus Medical (GMED) or Penumbra (PEN). But which of these two stocks presents investors with the better value opportunity right now?

GMED vs. PEN: Which Stock Should Value Investors Buy Now?

See News Rankings

Price charts implemented using Lightweight Charts™